Diabetes is one of today’s greatest global health challenges, affecting the lives of more than 425 million people worldwide.¹ Most live in low- and middle-income countries where access to reliable and affordable supplies of insulin can be a challenge for many.¹,² In addition, people with diabetes living in humanitarian crisis situations can experience difficulty accessing insulin.

**Novo Nordisk Access to Insulin Commitment**

Olivia has type 1 diabetes and lives in Côte d’Ivoire.
Access to Insulin Commitment principles

- It is our ambition to continue to be the leading supplier of low-priced human insulin in the world. We wish to provide affordable insulin treatment to significantly more patients in low- and middle-income countries and we are committed to passing on possible future gains in production efficiency to patients.

- We guarantee that we will provide low-priced human insulin to ensure access to quality treatments for patients in the poorest parts of the world for many years to come. Our guarantee applies to Least Developed Countries (LDCs) as defined by the UN, 3 other low-income countries as defined by the World Bank as well as middle-income countries where large low-income populations lack sufficient health coverage. For the selected humanitarian organisations, the commitment is global in scope.

- Our guarantee entails that we will provide the human insulin needed at a guaranteed ceiling price. The annual ceiling price will be decided by our Executive Management. The ceiling price for 2019 is set at 4.00 US dollars per vial. The ceiling price applies unless the price is determined by local agreements. The product supplied under this guarantee will be human insulin in vials.

Discover more at novonordisk.com/accesstocare